This study aims to evaluate a treatment called IBI3028 for patients with certain types of cancer that cannot be removed through surgery or have spread to other parts of the body. It's an open-label study, meaning both doctors and participants know what treatment is being given. To join, participants must be 18 or older, understand and agree to the study terms, and have a specific type of cancer that meets study criteria. They should have a life expectancy of at least 12 weeks and certain health conditions related to bone marrow, liver, kidneys, heart, and lungs must be met before participation.
- Participants will need to have regular visits for study assessments.
- There are specific health conditions required for eligibility.
- Participants cannot join if they are in other clinical trials or have had certain treatments recently.